Ceribell, Inc. Annual Report - Verified Summary for Investors

(Based on the 10-K filing for the fiscal year ended December 31, 2025)

1. Business Overview

Ceribell, Inc. is a medical technology company that improves neurological care. It develops and commercializes innovative, rapid, and portable electroencephalography (EEG) systems. Its flagship "Ceribell System" quickly detects and monitors seizures, especially in critical care settings. The company provides accessible and timely neurological insights to enhance patient outcomes in acute care environments.

2. Financial Performance

Ceribell achieved strong financial growth in fiscal year 2025, reporting total revenue of $78.5 million—a 32% increase year-over-year. Expanded sales of the Ceribell System and consumables across a growing network of hospitals primarily drove this growth. Despite this, the company reported a net loss of $42.1 million. This loss reflects significant ongoing investments in research and development (R&D) for new product features and indications, as well as commercial expansion efforts. Gross margin improved slightly to 68%, indicating better cost management on product sales. R&D expenses, at approximately 45% of revenue, underscore the company's commitment to innovation and future growth.

3. Risk Factors

Investors should consider several key risks that could impact Ceribell's operations and financial performance:

• Regulatory Approval & Compliance: Operating in a highly regulated environment, Ceribell faces risks from delays or failures in obtaining or maintaining FDA approvals for new products or indications.
• Reimbursement Uncertainty: Changes in healthcare reimbursement policies or inadequate coverage for Ceribell's products could limit market adoption and revenue.
• Intense Competition: The highly competitive medical device market means Ceribell faces pressure on pricing and market share from larger, established companies and new innovators.
• Intellectual Property Protection: Protecting its proprietary technology and defending against infringement claims is crucial for maintaining Ceribell's competitive advantage.
• Product Liability: As a medical device company, Ceribell faces inherent product liability risks, potentially leading to significant financial and reputational damage.
• Dependence on Key Personnel: Ceribell's success depends heavily on attracting and retaining highly skilled scientific, technical, and commercial personnel.
• Supply Chain Volatility: Intermittent disruptions in the supply of electronic components could lead to production delays and impact product availability.

4. Management Discussion (MD&A highlights)

In fiscal year 2025, Ceribell achieved solid operational progress, marked by increased adoption of its core system and strategic product development, even while navigating a dynamic healthcare landscape.

Key Achievements:

• Expanded Market Penetration: Added 150 new hospital accounts, expanding its installed base to over 800 facilities and demonstrating strong market acceptance.
• Product Enhancements: Launched a significant software update for the Ceribell System, introducing enhanced AI-powered seizure detection algorithms and an improved user interface. This reinforces Ceribell's technological leadership.
• Clinical Validation: Published two new peer-reviewed studies. These studies further validate the technology's clinical utility and cost-effectiveness in emergency and critical care settings, strengthening market credibility.
• Strategic Partnership: Secured a distribution agreement with a major international medical device distributor, laying the groundwork for future global expansion.

Significant Challenges:

• Supply Chain Volatility: Experienced intermittent disruptions in electronic component supply, leading to minor production delays that required proactive management.
• Reimbursement Hurdles: Continued to face challenges securing consistent and favorable reimbursement policies across all payer networks. This impacted sales cycles in some regions and necessitated ongoing advocacy.
• Intensifying Competition: Navigated an increasingly competitive landscape. Both established medical device companies and new entrants are developing similar technologies, requiring continuous innovation and market differentiation.

The executive leadership team remained stable in fiscal year 2025. The company remains steadfast in its strategic direction, focusing on three core pillars: Market Expansion, Product Innovation, and Operational Excellence. Management also highlighted broader market trends aligning with Ceribell's strategy: growing demand for neurological monitoring, the shift towards point-of-care diagnostics, and increasing AI integration in healthcare. The company closely monitors potential changes in FDA regulations for AI-driven medical devices and evolving reimbursement policies, which could impact market access and profitability.

5. Financial Health

Ceribell demonstrated strong financial health as of December 31, 2025, holding $115.3 million in cash and cash equivalents. The company reported no significant long-term debt, relying primarily on equity financing for operations and growth. Its current ratio of 2.5x indicates strong short-term liquidity and ability to meet immediate financial obligations. The public float of Ceribell's common stock was approximately $417.2 million as of June 30, 2025. As of February 20, 2026, 37,641,229 shares of common stock were outstanding.

6. Future Outlook

Ceribell has outlined an ambitious roadmap for the coming year and beyond, focusing on its strategic pillars: Market Expansion, Product Innovation, and Operational Excellence. The company aims to:

• Drive Customer Growth: Expand its installed base to over 1,000 hospitals by the end of 2026, focusing on new customer acquisition and deeper penetration within existing accounts.
• Innovate Product Offerings: Launch at least two significant software or hardware updates for the Ceribell System, potentially including new monitoring capabilities or expanded indications beyond seizures, leveraging AI-powered algorithms.
• Explore New Markets: Initiate pilot programs for international market entry in key European and Asian regions, building on its recent distribution partnership.
• Advance Technological Edge: Further enhance its AI-powered diagnostic algorithms and explore integration with broader hospital IT systems to improve workflow efficiency.
• Strengthen Operations: Invest in scaling its commercial team and optimizing its supply chain to support anticipated growth, while also exploring strategic partnerships or acquisitions.
• Secure Future Funding: Continuously evaluate capital needs and explore various financing options to support long-term growth. The company anticipates continued net losses in the near term as it prioritizes market expansion and R&D to achieve long-term profitability.

7. Competitive Position

Ceribell stands out with its innovative, portable, and user-friendly EEG system, offering rapid seizure detection capabilities often within minutes. This speed and ease of use provide a significant advantage in critical care settings where time is critical, addressing an unmet need for immediate neurological assessment. Proprietary AI-powered algorithms and a growing body of clinical evidence further bolster its competitive edge, validating the system's clinical utility and cost-effectiveness. While competing with established neurological monitoring companies and emerging tech firms offering alternative or complementary solutions, Ceribell aims to maintain leadership in rapid, point-of-care EEG solutions. It does this by continuously enhancing its technology, expanding clinical applications, and focusing on user-centric design.